Journal
JOURNAL OF PATHOLOGY
Volume 229, Issue 3, Pages 469-476Publisher
WILEY
DOI: 10.1002/path.4134
Keywords
mucinous ovarian cancer; RNF43; somatic mutation; DNA sequencing
Funding
- Victorian Breast Cancer Research Consortium (VBCRC)
- National Health and Medical Research Council of Australia (NHMRC) [628733]
- Victorian Government's Operational Infrastructure Support Programme
- Emer Casey Foundation
- US Army Medical Research and Materiel Command [DAMD17-01-1-0729]
- Cancer Council Tasmania
- Cancer Foundation of Western Australia and the NHMRC [400413]
- Australian Postgraduate Award
Ask authors/readers for more resources
Mucinous carcinomas represent a distinct morphological subtype which can arise from several organ sites, including the ovary, and their genetic characteristics are largely under-described. Exome sequencing of 12 primary mucinous ovarian tumours identified RNF43 as the most frequently somatically mutated novel gene, secondary to KRAS and mutated at a frequency equal to that of TP53 and BRAF. Further screening of RNF43 in a larger cohort of ovarian tumours identified additional mutations, with a total frequency of 2/22 (9%) in mucinous ovarian borderline tumours and 6/29 (21%) in mucinous ovarian carcinomas. Seven mutations were predicted to truncate the protein and one missense mutation was predicted to be deleterious by in silico analysis. Six tumours had allelic imbalance at the RNF43 locus, with loss of the wild-type allele. The mutation spectrum strongly suggests that RNF43 is an important tumour suppressor gene in mucinous ovarian tumours, similar to its reported role in mucinous pancreatic precancerous cysts. Copyright (C) 2012 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available